New obesity drug shows promising weight loss results in clinical trials.

Eli Lilly's diabetes drug Mounjaro has helped patients lose 15.7% of their body weight in a clinical trial, paving the way for its approval as a weight loss treatment. Mounjaro is in the same class as Novo Nordisk's Ozempic and has shown the potential to lead to even greater weight loss. Analysts expect Mounjaro to generate billions of dollars in annual sales, with projections of up to $26.4 billion by 2030.